Encompass Health (EHC) reported $1.46 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 12%. EPS of $1.40 for the same period compares to $1.11 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.43 billion, representing a surprise of +2.29%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $1.20.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Encompass Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net patient revenue per discharge: $21,670.00 versus the two-analyst average estimate of $21,429.50.
- Discharges: 65,237 compared to the 64,850 average estimate based on two analysts.
- Net Operating Revenues- Inpatient: $1.41 billion versus the two-analyst average estimate of $1.39 billion. The reported number represents a year-over-year change of +11.7%.
- Net Operating Revenues- Outpatient and other: $44 million versus the two-analyst average estimate of $43.19 million. The reported number represents a year-over-year change of +23.3%.
View all Key Company Metrics for Encompass Health here>>>
Shares of Encompass Health have returned -8.8% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Encompass Health Corporation (EHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
